Pediatric Intracranial Ependymoma - Recommendations for
First-Line Treatment from the German HIT-MED study group

J 2023

Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER et. al.

Základní údaje

Originální název

Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group

Autoři

Vydání

Klinische Pädiatrie, Stuttgart, Georg Thieme Verlag, 2023, 0300-8630

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

SIOP

Impakt faktor

Impact factor: 1.000 v roce 2022

Kód RIV

RIV/00216224:90249/23:00132052

Organizační jednotka

CZECRIN IV

DOI

http://dx.doi.org/10.1055/a-2070-7572

UT WoS

001058665800004

Klíčová slova česky

ependymoma; guideline; radiotherapy; chemotherapy; children

Klíčová slova anglicky

ependymoma; guideline; radiotherapy; chemotherapy; children

Štítky

Excelence Science, INT, neMU, RIV, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 4. 2024 12:58, Mgr. Michal Petr

Anotace

V originále

Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged > 1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN a Stefan RUTKOWSKI. Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group. Klinische Pädiatrie. Stuttgart: Georg Thieme Verlag, 2023, roč. 235, č. 3, s. 167-177. ISSN 0300-8630. Dostupné z: https://dx.doi.org/10.1055/a-2070-7572.

@article{2330760,
   author = {Obrecht, Denise and Mynarek, Martin and StickanandVerfuerth, Martina and Bison, Brigitte and Schueller, Ulrich and Pajtler, Kristian and Hagel, Christian and Thomale, UlrichandWilhelm and Fleischhack, Gudrun and Timmermann, Beate and Rutkowski, Stefan},
   article_location = {Stuttgart},
   article_number = {3},
   doi = {http://dx.doi.org/10.1055/a-2070-7572},
   keywords = {ependymoma; guideline; radiotherapy; chemotherapy; children},
   language = {eng},
   issn = {0300-8630},
   journal = {Klinische Pädiatrie},
   title = {Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group},
   url = {https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2070-7572},
   volume = {235},
   year = {2023}
}

TY  - JOUR
ID  - 2330760
AU  - Obrecht, Denise - Mynarek, Martin - Stickan-Verfuerth, Martina - Bison, Brigitte - Schueller, Ulrich - Pajtler, Kristian - Hagel, Christian - Thomale, Ulrich-Wilhelm - Fleischhack, Gudrun - Timmermann, Beate - Rutkowski, Stefan
PY  - 2023
TI  - Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group
JF  - Klinische Pädiatrie
VL  - 235
IS  - 3
SP  - 167-177
EP  - 167-177
PB  - Georg Thieme Verlag
SN  - 03008630
KW  - ependymoma
KW  - guideline
KW  - radiotherapy
KW  - chemotherapy
KW  - children
UR  - https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2070-7572
N2  - Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged > 1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.
ER  -

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN a Stefan RUTKOWSKI. Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group. \textit{Klinische Pädiatrie}. Stuttgart: Georg Thieme Verlag, 2023, roč.~235, č.~3, s.~167-177. ISSN~0300-8630. Dostupné z: https://dx.doi.org/10.1055/a-2070-7572.

Podrobný výpis o publikaci